UBS analyst David Dai reiterated a Buy rating and $45.00 price target on Celldex Therapeutics (NASDAQ: CLDX).The analyst commented, "CLDX ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE